preprints_ui: bhpx8_v1
Data license: ODbL (database) & original licenses (content) · Data source: Open Science Framework
| id | title | description | date_created | date_modified | date_published | original_publication_date | publication_doi | provider | is_published | reviews_state | version | is_latest_version | preprint_doi | license | tags_list | tags_data | contributors_list | contributors_data | first_author | subjects_list | subjects_data | download_url | has_coi | conflict_of_interest_statement | has_data_links | has_prereg_links | prereg_links | prereg_link_info | last_updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bhpx8_v1 | ACE2: THE DOORWAY TO SARS-CoV-2 | The angiotensin-converting enzyme 2 (ACE2) is the host functional receptor for the new virus SARS-CoV-2 causing Coronavirus Disease 2019. ACE2 is expressed in 71 different cell types. Some factors that can affect the expression of the ACE2 are: sex, environment, lifestyles, comorbidities, medications (e.g. anti-hypertensives) and its interaction with other genes of the renin-angiotensin system and other pathways. All of these factors can affect the risk of infection of SARS-CoV-2 and determine the severity of the symptoms. The ACE2 enzyme is a negative regulator of RAS expressed in various organ systems. It has been seen to be associated with immunity, inflammation, increased coagulopathy, and cardiovascular disease. In this review, we describe the genetic and molecular functions of the ACE2 receptor and its relation with the physiological and pathological conditions to better understand how this receptor is involved in the pathogenesis of COVID-19. | 2020-10-21T15:48:11.689702 | 2020-10-22T02:04:39.873976 | 2020-10-22T01:02:44.337747 | frenxiv | 1 | accepted | 1 | 1 | https://doi.org/10.31226/osf.io/bhpx8 | CC-By Attribution 4.0 International | ACE2; COVID-19; Coronavirus; SARS-CoV-2 | ["ACE2", "COVID-19", "Coronavirus", "SARS-CoV-2"] | Miriam Marlene Medina-Enríquez; José Alberto Carlos-Escalante; Zuleika Aponte-Torres; Angelica Cuapio; Sandra Lopez-Leon; Talia Wegman-Ostrosky | [{"id": "jwmzh", "name": "Miriam Marlene Medina-Enr\u00edquez", "index": 0, "orcid": "0000-0001-9454-9114", "bibliographic": true}, {"id": "f7amd", "name": "Jos\u00e9 Alberto Carlos-Escalante", "index": 1, "orcid": null, "bibliographic": true}, {"id": "cys3r", "name": "Zuleika Aponte-Torres", "index": 2, "orcid": null, "bibliographic": true}, {"id": "jytxu", "name": "Angelica Cuapio", "index": 3, "orcid": null, "bibliographic": true}, {"id": "9xcmw", "name": "Sandra Lopez-Leon", "index": 4, "orcid": null, "bibliographic": true}, {"id": "dfuj8", "name": "Talia Wegman-Ostrosky", "index": 5, "orcid": null, "bibliographic": true}] | Miriam Marlene Medina-Enríquez | Medicine and Health Sciences; Medical Sciences; Medical Cell Biology | [{"id": "5a57dc25076808000d815753", "text": "Medicine and Health Sciences"}, {"id": "5a57dc2e076808000d81585e", "text": "Medical Sciences"}, {"id": "5a57dc3c076808000d815ae4", "text": "Medical Cell Biology"}] | https://osf.io/download/5f90584c73f0e100d8bbbae2 | 1 | SLL is employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declare | not_applicable | not_applicable | [] | 2025-04-09T20:03:38.969359 |